Phase III Study Demonstrates INVEGA® SUSTENNA(TM) Statistically Similar to RISPERDAL® CONSTA® Long-Acting Injection

A December 10th news release from PR Newswire:

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

To read the entire news release, please click here

Extended-Release Injectable Paliperidone Approved in the US for Schizophrenia

A news release posted today by docguide.com:

The US Food and Drug Administration (FDA) today approved paliperidone palmitate (Invega Sustenna) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the United States for this use.

Bold emphasis in the text is mine.

To read the entire news release, please click here.

Also see:

FDA Approves INVEGA® SUSTENNA™ for the Acute and Maintenance Treatment of Schizophrenia

FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia

Monthly Shot Treats Schizophrenia